Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
作者: Kohei ShitaraHiroki HaraTakaki YoshikawaKazumasa FujitaniTomohiro NishinaAyumu HosokawaTakashi AsakawaSatoe KawakamiKei Muro
作者单位: 1Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan
2Department of Gastroenterology, Saitama Cancer Center, 780 Komuro, 362-0806, Ina, Saitama, Japan
3Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakano, Asahi-ku, 241-8515, Yokohama, Japan
4Department of Gastric Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 104-0045, Tokyo, Japan
5Department of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi Sumiyoshi-ku, 558-8558, Osaka, Japan
6Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Kou-160, Minamiumemoto-machi, Matsuyama, Ehime, Japan
7Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, 930-0194, Toyama, Toyama, Japan
8Department of Clinical Oncology, University of Miyazaki Hospital, 5200 Kiyotakecho Kihara, 889-1692, Miyazaki, Miyazaki, Japan
9Clinical Information and
刊名: International Journal of Clinical Oncology, 2020, Vol.25 (2), pp.301-311
来源数据库: Springer Nature Journal
DOI: 10.1007/s10147-019-01558-z
关键词: PertuzumabTrastuzumabMetastatic gastric cancerMetastatic gastroesophageal junction cancerJapanese subgroup analysisPhase III
英文摘要: Abstract(#br)Background(#br)The phase III JACOB trial (NCT01774786) compared the efficacy and safety of pertuzumab and trastuzumab plus chemotherapy with placebo and trastuzumab plus chemotherapy in patients with previously untreated human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gastroesophageal junction cancer. We conducted a subgroup analysis in Japanese patients. Methods(#br)Patients were randomized 1:1 to pertuzumab 840 mg or placebo, plus trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) and chemotherapy (cisplatin 80 mg/m2, and capecitabine 1000 mg/m2 twice daily for 28 doses or 5-fluorouracil 800 mg/m2 every 24 h for 120 h), every 3 weeks. Continuation of chemotherapy after 6 cycles was at the discretion...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:1.727 (2012)

×